Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Liver X Receptor (LXR)-β Regulation in LXRα-Deficient Mice: Implications for Therapeutic Targeting

Elaine M. Quinet, Dawn A. Savio, Anita R. Halpern, Liang Chen, Gertrude U. Schuster, Jan-Åke Gustafsson, Mike D. Basso and Ponnal Nambi
Molecular Pharmacology October 2006, 70 (4) 1340-1349; DOI: https://doi.org/10.1124/mol.106.022608
Elaine M. Quinet
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dawn A. Savio
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anita R. Halpern
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liang Chen
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gertrude U. Schuster
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jan-Åke Gustafsson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mike D. Basso
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ponnal Nambi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The nuclear receptors liver X receptor (LXR) LXRα and LXRβ are differentially expressed ligand-activated transcription factors that induce genes controlling cholesterol homeostasis and lipogenesis. Synthetic ligands for both receptor subtypes activate ATP binding cassette transporter A1 (ABCA1)-mediated cholesterol metabolism, increase reverse cholesterol transport, and provide atheroprotection in mice. However, these ligands may also increase hepatic triglyceride (TG) synthesis via a sterol response element binding protein 1c (SREBP-1c)-dependent mechanism through a process reportedly regulated by LXRα. We studied pan-LXRα/β agonists in LXRα knockout mice to assess the contribution of LXRβ to the regulation of selected target genes. In vitro dose-response studies with macrophages from LXRα-/- and β-/- mice confirm an equivalent role for LXRα and LXRβ in the regulation of ABCA1 and SREBP-1c gene expression. Cholesterol-efflux studies verify that LXRβ can drive apoA1-dependent cholesterol mobilization from macrophages. The in vivo role of LXRβ in liver was further evaluated by treating LXRα-/- mice with a pan-LXRα/β agonist. High-density lipoprotein (HDL) cholesterol increased without significant changes in plasma TG or very low density lipoprotein. Analysis of hepatic gene expression consistently revealed less activation of ABCA1 and SREBP-1c genes in the liver of LXRα null animals than in treated wild-type controls. In addition, hepatic CYP7A1 and several genes involved in fatty acid/TG biosynthesis were not induced. In peripheral tissues from these LXRα-null mice, LXRβ activation increases ABCA1 and SREBP-1c gene expression in a parallel manner. However, putative elevation of SREBP-1c activity in these tissues did not cause hypertriglyceridemia. In summary, selective LXRβ activation is expected to stimulate ABCA1 gene expression in macrophages, contribute to favorable HDL increases, but circumvent hepatic LXRα-dominated lipogenesis.

Footnotes

  • The generation of LXR isoform-deleted mice was supported by grants from the Swedish Science Council and from KaroBio AB.

  • ABBREVIATIONS: LXR, liver X receptor; ABCA1, ATP binding cassette transporter A1; VLDL, very low density lipoprotein; CYP7A1, cholesterol 7α hydroxylase; angptl3, angiopoietin-like protein 3; apoCI, apolipoprotein CI; DMEM, Dulbecco's modified Eagle's medium; HDL, high-density lipoprotein; LDL, low-density lipoprotein; CETP, cholesteryl ester transfer protein; TG, triglyceride; RCT, reverse cholesterol transport; SCD1, stearoyl CoA desaturase-1; KO, knockout; FAS, fatty acid synthase; WT, wild-type; PCR, polymerase chain reaction; BSA, bovine serum albumin; FBS, fetal bovine serum; SREBP-1c, sterol-response element binding protein; TO901317, N-(2,2,2,-trifluoro-ethyl)-N-[4-(2,2,2,-trifluoro-1-hydroxy-1-trifluoromethyl-ethyl)-phenyl]-benzenesulfonamide; GW3965, 3-(3-(2-chloro-3-trifluoromethylbenzyl-2,2-diphenylethylamino) proproxy) phenylacetic acid.

    • Received January 17, 2006.
    • Accepted July 6, 2006.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 70 (4)
Molecular Pharmacology
Vol. 70, Issue 4
1 Oct 2006
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Liver X Receptor (LXR)-β Regulation in LXRα-Deficient Mice: Implications for Therapeutic Targeting
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Liver X Receptor (LXR)-β Regulation in LXRα-Deficient Mice: Implications for Therapeutic Targeting

Elaine M. Quinet, Dawn A. Savio, Anita R. Halpern, Liang Chen, Gertrude U. Schuster, Jan-Åke Gustafsson, Mike D. Basso and Ponnal Nambi
Molecular Pharmacology October 1, 2006, 70 (4) 1340-1349; DOI: https://doi.org/10.1124/mol.106.022608

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Liver X Receptor (LXR)-β Regulation in LXRα-Deficient Mice: Implications for Therapeutic Targeting

Elaine M. Quinet, Dawn A. Savio, Anita R. Halpern, Liang Chen, Gertrude U. Schuster, Jan-Åke Gustafsson, Mike D. Basso and Ponnal Nambi
Molecular Pharmacology October 1, 2006, 70 (4) 1340-1349; DOI: https://doi.org/10.1124/mol.106.022608
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Mechanism of the selective action of paraherquamide A
  • Fatty Acid Amide Hydrolase in Cisplatin Nephrotoxicity
  • Use-Dependent Relief of A-887826 Inhibition
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics